Invivo Therapeutics Holdings Corp (OTCBB - OTCQB:NVIV)
| 2.89 Data as of 3:49pm ET |  0.00 / 0.00%Today’s Change | 1.25 Today|||52-Week Range 3.79 | +66.09% Year-to-Date |
Latest NVIV News | Press Releases
No recent news for Invivo Therapeutics Holdings Corp.
Today’s Trading
| Previous close | 2.89 |
| Today’s open | 2.88 |
| Day’s range | 2.85 - 2.90 |
| Volume | 101,124 |
| Average volume (3 months) | 273,435 |
| Market cap | $202.8M |
| Dividend yield | -- |
Data as of 3:49pm ET, 05/20/2013
Growth & Valuation
| Earnings growth (last year) | -- |
| Earnings growth (this year) | -72.22% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | -- |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ACTCAdvanced Cell Techno... | -0.00 | -5.61% |
| SLNCFSilence Therapeutics... | 0.00 | 0.00% |
| IMUCImmunoCellular Thera... | -0.02 | -0.78% |
| DYAXDyax Corp | -0.02 | -0.79% |
Data as of 4:02pm ET, 05/20/2013
Financials
| Next reporting date | August 15, 2013 |
| EPS forecast (this quarter) | -$0.07 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | $4.7M |
| Net profit margin | -- |
Profile
Sector Industrial Services |
Industry Engineering & Construction |
Chairman, President, CEO & Chief Financial Officer Frank M. Reynolds, MBA |
Chief Science Officer Brian Hess |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
